what is the difference between glp-1 and glp-3 Clinical Focus on Agonists in Type 2 Diabetes Mellitus GLP-3 RT (LY3437943) — Triple-Action

When GLP-1 treatments hit the market in the early 2000s, Breakthrough T1D and others funded several clinical trials to test whether GLP-1 receptor agonists, in addition to insulin, improved outcomes for people with type 1 diabetes

It does not usually cause dangerous changes to blood sugar or stop the medicine working, but keeping injections on a consistent weekly schedule is the safest approach

Last reviewed: June 1, 2026 Last updated: June 1, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations

PPAR- is expressed in VSMCs, where its activation reduces oxidative stress and suppresses pro-inflammatory signaling [147]

Meta-analyses that pool these trials have reached the same conclusion: no statistically significant increase in pancreatitis attributable to the drug class

Understanding the Obesity Epidemic Obesity is a global epidemic affecting millions, with 1 in 8 adults worldwide classified as obese